TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Status:
Recruiting
Trial end date:
2024-06-23
Target enrollment:
Participant gender:
Summary
This is a phase 1/1b open label, multicenter dose escalation and dose expansion study to
investigate the safety, tolerability and anti-tumor activity of TPST-1120, a small molecule
selective antagonist of PPARĪ± (peroxisome proliferator activated receptor alpha) as
monotherapy and in combination with a systemic anticancer agent, nivolumab, an anti-PD1
antibody, in subjects with advanced solid tumors.